Publicaciones en las que colabora con Iago Rodríguez Lago (14)

2024

  1. Effectiveness and safety of azathioprine for inflammatory pouch disorders: results from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  3. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

  4. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease

2023

  1. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

2022

  1. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

    Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058

  2. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 10, pp. 737-741

2021

  1. ¿Qué debe conocer el cirujano del diagnóstico y tratamiento médico de la enfermedad de Crohn intestinal?

    Prácticum en coloproctología de la ACPE: estrategias y técnicas para la práctica diaria (Ergon), pp. 343-353

2020

  1. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease

    United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066

  2. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 6, pp. 1017-1030

  3. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease

    Alimentary Pharmacology and Therapeutics, Vol. 51, Núm. 9, pp. 870-879

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 2, pp. 90-101

  3. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 3, pp. 278-288